Immunocore Reveals Promising Brenetafusp Trial Results
Company Announcements

Immunocore Reveals Promising Brenetafusp Trial Results

An update from Immunocore Holdings (IMCR) is now available.

Immunocore Holdings plc announced promising results from its Phase 1 trial of a new cancer treatment, brenetafusp, for melanoma patients previously treated with immune checkpoints. The findings are set to be presented at the ASCO Annual Meeting and will be further discussed in a conference call and webcast. Investors and interested parties can access the webcast via the company’s website to learn about the potential impact on melanoma treatment.

For an in-depth examination of IMCR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskImmunocore Holdings Plc Reports Strong Q3 Revenue Growth
TheFlyImmunocore reports Q3 EPS 17c, consensus (35c)
TheFlyImmunocore reports cash, equivalents of $901.3M as of September 30
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App